Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (currently amended) A compound of the formula:



or the pharmaceutically acceptable acid salts thereof wherein:

R_1 is halogen or C_1-C_4 alkyl;

R_2 represents halogen, C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 alkylthio, hydroxy, amino, mono C_1-C_4 alkylamino or di C_1-C_4 alkylamino,

R_3 represesents hydrogen, halogen, C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 alkylthio, hydroxy, amino, mono C_1-C_4 alkylamino or di C_1-C_4 alkylamino,

with the proviso that R_2 and R_3 may not be 2-isopropoxyl and hydrogen respectively when R_1 is bromo;

wherein in an in vitro assay for D2 receptor binding employing YM 09151-2 radioligand and homogenized COS cells containing recombinantly produced human D2 receptors, the compound exhibits a Ki value of greater than 300 nM.

2. (Original) A compound according to Claim 1, wherein R_1 is methyl.

3. (currently amended) A compound of the formula:



or the pharmaceutically acceptable salts thereof wherein

R_x is fluorine, chlorine, bromine, or iodine; and

R_2 and R_3 are the same or different and represent hydrogen, halogen, C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 alkylthio, hydroxy, amino, mono C_1-C_4 alkylamino or di C_1-C_4 alkylamino;

with the proviso that R_2 and R_3 may not be 2-isopropoxyl and hydrogen, respectively, when R_x is bromo; and

wherein in an in vitro assay for D2 receptor binding employing YM 09151-2 radioligand and homogenized COS cells containing recombinantly produced human D2 receptors, the compound exhibits a Ki value of greater than 300 nM.

4. (canceled)

5. (Previously presented) A compound according to claim 3, wherein R_x is chloride; R_2 is chloride, methyl, ethoxy or methoxy; and R_3 is chloride, hydrogen or methyl.

6. (Original) A compound according to claim 5, wherein the phenyl group substituted with R_2 and R_3 is selected from the group consisting of:



7. (currently amended) A compound of the formula:



or the pharmaceutically acceptable salts thereof wherein

R_a is C_1-C_4 alkyl; and

R_2 represents halogen, C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 alkylthio, hydroxy, amino, mono C_1-C_4 alkylamino or di C_1-C_4 alkylamino;

R_3 represents hydrogen, halogen, C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 alkylthio, hydroxy, amino, mono C_1-C_4 alkylamino or di C_1-C_4 alkylamino;

wherein in an in vitro assay for D2 receptor binding employing YM 09151-2 radioligand and homogenized COS cells containing recombinantly produced human D2 receptors, the compound exhibits a Ki value of greater than 300 nM.

8. (previously presented) A compound according to Claim 7, wherein R_a is methyl.

9. (Original) A compound of according to Claim 7, wherein R_2 is chloride, fluoride, methyl or methoxy; and R_3 is hydrogen or methyl.

10. (Original) A compound according to claim 8, wherein the phenyl group substituted with R_2 and R_3 is selected from the group consisting of:



11. (currently amended) A compound of the formula:



or the pharmaceutically acceptable salts thereof wherein:

R_1 is C_1-C_4 alkyl or halogen; and

wherein in an in vitro assay for D2 receptor binding employing YM 09151-2 radioligand and homogenized COS cells containing recombinantly produced human D2 receptors, the compound exhibits a Ki value of greater than 300 nM.

12. (Original) A compound according to Claim 11, wherein R_1 is chloro.

13-35. (Canceled)

36. (Previously presented) A compound according to claim 1 wherein the Ki value is greater than 600 nM.

37. (Previously presented) A compound according to claim 1 wherein the Ki value is greater than 1000 nM.

38. (Previously presented) A compound according to claim 3 wherein the Ki value of greater than 600 nM.

39. (Previously presented) A compound according to claim 3 wherein the Ki value is greater than 1000 nM.

40. (Previously presented) A compound according to claim 7 wherein the Ki value is greater than 600 nM.

41. (Previously presented) A compound according to claim 7 wherein the Ki value is greater than 1000 nM.

42. (Previously presented) A compound according to claim 11 wherein the Ki value is greater than 600 nM.

43. (Previously presented) A compound according to claim 11 wherein the Ki value is greater than 1000 nM.

44. (currently amended) A compound of the formula:



or the pharmaceutically acceptable acid salts thereof wherein:

R_1 is halogen or C_1-C_4 alkyl;

R_2 represents halogen, C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 alkylthio, hydroxy, amino, mono C_1-C_4 alkylamino or di C_1-C_4 alkylamino,

R_3 represents hydrogen, halogen, C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 alkylthio, hydroxy, amino, mono C_1-C_4 alkylamino or di C_1-C_4 alkylamino,

with the proviso that R_2 and R_3 may not be 2-isopropoxyl and hydrogen respectively when R_1 is bromo;

wherein in an in vitro assay for D4 receptor binding employing YM 09151-2 radioligand and homogenized COS cells containing recombinantly produced human D4 receptors, the compound exhibits a Ki value of 16 nM or less.

45. (Previously presented) A compound according to Claim 44, wherein R_1 is methyl.

46. (currently amended) A compound of the formula:



or the pharmaceutically acceptable salts thereof wherein

R_x is fluorine, chlorine, bromine, or iodine; and

R_2 and R_3 are the same or different and represent hydrogen, halogen, C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 alkylthio, hydroxy, amino, mono C_1-C_4 alkylamino or di C_1-C_4 alkylamino;

wherein in an in vitro assay for D4 receptor binding employing YM 09151-2 radioligand and homogenized COS cells containing recombinantly produced human D4 receptors, the compound exhibits a Ki value of 16 nM or less.

47. (Previously presented) A compound according to Claim 46, wherein R_2 and R_3 may not be 2-isopropoxyl and hydrogen, respectively, when R_1 is bromo.

48. (Previously presented) A compound according to claim 46, wherein R_x is chloride; R_2 and R_3 may not be 2-isopropoxyl and hydrogen, respectively, when R_1 is bromo; R_2 is chloride, methyl or methoxy; and R_3 is hydrogen or methyl.

49. (Previously presented) A compound according to claim 48, wherein the phenyl group substituted with R_2 and R_3 is selected from the group consisting of:



50. (currently amended) A compound of the formula:



or the pharmaceutically acceptable salts thereof wherein

R_a is C_1-C_4 alkyl; and

R_2 represents halogen, C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 alkylthio, hydroxy, amino, mono C_1-C_4 alkylamino or di C_1-C_4 alkylamino;

R_3 represents hydrogen, halogen, C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 alkylthio, hydroxy, amino, mono C_1-C_4 alkylamino or di C_1-C_4 alkylamino;

wherein in an in vitro assay for D4 receptor binding employing YM 09151-2 radioligand and homogenized COS cells containing recombinantly produced human D4 receptors, the compound exhibits a Ki value of 16 nM or less.

51. (Previously presented) A compound according to Claim 50, wherein R_1 is methyl.

52. (Previously presented) A compound of according to Claim 50, wherein R_2 is chloride, fluoride, methyl or methoxy; and R_3 is hydrogen or methyl.

53. (Previously presented) A compound according to claim 51, wherein the phenyl group substituted with R_2 and R_3 is selected from the group consisting of:



54. (currently amended) A compound of the formula:



or the pharmaceutically acceptable salts thereof wherein:

R_1 is C_1-C_4 alkyl or halogen; and

wherein in an in vitro assay for D4 receptor binding employing YM 09151-2 radioligand and homogenized COS cells containing recombinantly produced human D4 receptors, the compound exhibits a Ki value of 16 nM or less.

55. (Previously presented) A compound according to Claim 54, wherein R_1 is chloro.

56. (currently amended) A compound of the formula:



or the pharmaceutically acceptable acid salts thereof wherein:

R_1 is halogen or C_1-C_4 alkyl;

R_2 represents halogen, C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 alkylthio, hydroxy, amino, mono C_1-C_4 alkylamino or di C_1-C_4 alkylamino,

R_3 represents hydrogen, halogen, C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 alkylthio, hydroxy, amino, mono C_1-C_4 alkylamino or di C_1-C_4 alkylamino,

with the proviso that R_2 and R_3 may not be 2-isopropoxyl and hydrogen respectively when R_1 is bromo;

wherein in an assay for D2 receptor binding the compound exhibits a Ki value of greater than 300 nM, and wherein in an assay for D4 receptor binding the compound exhibits a Ki value of 16 nM or less, wherein each assay is an in vitro assay employing YM 09151-2 radioligand and homogenized COS cells containing recombinantly produced human receptors.

57. (Previously presented) A compound according to Claim 56, wherein R_1 is methyl.

58. (currently amended) A compound of the formula:



or the pharmaceutically acceptable salts thereof wherein

R_x is fluorine, chlorine, bromine, or iodine; and

R_2 and R_3 are the same or different and represent hydrogen, halogen, C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 alkylthio, hydroxy, amino, mono C_1-C_4 alkylamino or di C_1-C_4 alkylamino;

wherein in an assay for D2 receptor binding the compound exhibits a Ki value of greater than 300 nM, and wherein in an assay for D4 receptor binding the compound exhibits a Ki value of 16 nM or less, wherein each assay is an in vitro assay employing YM 09151-2 radioligand and homogenized COS cells containing recombinantly produced human receptors.

59. (Previously presented) A compound according to Claim 58, wherein R_2 and R_3 may not be 2-isopropoxyl and hydrogen, respectively, when R_1 is bromo.

60. (Previously presented) A compound according to claim 58, wherein R_x is chloride; R_2 and R_3 may not be 2-isopropoxyl

and hydrogen, respectively, when R_1 is bromo; R_2 is chloride, methyl or methoxy; and R_3 is hydrogen or methyl.

61. (Previously presented) A compound according to claim 60, wherein the phenyl group substituted with R_2 and R_3 is selected from the group consisting of:



62. (currently amended) A compound of the formula:



or the pharmaceutically acceptable salts thereof wherein R_a is C_1-C_4 alkyl; and

R_2 represents halogen, C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 alkylthio, hydroxy, amino, mono C_1-C_4 alkylamino or di C_1-C_4 alkylamino;

R_3 represents hydrogen, halogen, C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 alkylthio, hydroxy, amino, mono C_1-C_4 alkylamino or di C_1-C_4 alkylamino;

wherein in an assay for D2 receptor binding the compound exhibits a Ki value of greater than 300 nM, and wherein in an assay for D4 receptor binding the compound exhibits a Ki value of 16 nM or less, wherein each assay is an in vitro assay employing YM 09151-2 radioligand and homogenized COS cells containing recombinantly produced human receptors.

63. (Previously presented) A compound according to Claim 62, wherein R_1 is methyl.

64. (Previously presented) A compound of according to Claim 62, wherein R_2 is chloride, fluoride, methyl or methoxy; and R_3 is hydrogen or methyl.

65. (Previously presented) A compound according to claim 63, wherein the phenyl group substituted with R_2 and R_3 is selected from the group consisting of:



66. (currently amended) A compound of the formula:



or the pharmaceutically acceptable salts thereof wherein:

R_1 is C_1-C_4 alkyl or halogen; and

wherein in an assay for D2 receptor binding the compound exhibits a Ki value of greater than 300 nM, and wherein in an assay for D4 receptor binding the compound exhibits a Ki value of 16 nM or less, wherein each assay is an in vitro assay employing YM 09151-2 radioligand and homogenized COS cells containing recombinantly produced human receptors.

67. (Previously presented) A compound according to Claim 66, wherein R_1 is chloro.